Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist von Parisi, Giulia, Saco, Justin D., Salazar, Felix B., Tsoi, Jennifer, Krystofinski, Paige, Puig-Saus, Cristina, Zhang, Ruixue, Zhou, Jing, Cheung-Lau, Gardenia C., Garcia, Alejandro J., Grasso, Catherine S., Tavaré, Richard, Hu-Lieskovan, Siwen, Mackay, Sean, Zalevsky, Jonathan, Bernatchez, Chantale, Diab, Adi, Wu, Anna M., Comin-Anduix, Begoña, Charych, Deborah, Ribas, Antoni

Volltext

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy von Charych, Deborah, Khalili, Samira, Dixit, Vidula, Kirk, Peter, Chang, Thomas, Langowski, John, Rubas, Werner, Doberstein, Stephen K, Eldon, Michael, Hoch, Ute, Zalevsky, Jonathan

Volltext

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy von Sharma, Meenu, Khong, Hiep, Fa’ak, Faisal, Bentebibel, Salah-Eddine, Janssen, Louise M. E., Chesson, Brent C., Creasy, Caitlin A., Forget, Marie-Andrée, Kahn, Laura Maria S., Pazdrak, Barbara, Karki, Binisha, Hailemichael, Yared, Singh, Manisha, Vianden, Christina, Vennam, Srinivas, Bharadwaj, Uddalak, Tweardy, David J., Haymaker, Cara, Bernatchez, Chantale, Huang, Shixia, Rajapakshe, Kimal, Coarfa, Cristian, Hurwitz, Michael E., Sznol, Mario, Hwu, Patrick, Hoch, Ute, Addepalli, Murali, Charych, Deborah H., Zalevsky, Jonathan, Diab, Adi, Overwijk, Willem W.

Volltext

Enhanced antibody half-life improves in vivo activity von Zalevsky, Jonathan, Chamberlain, Aaron K, Horton, Holly M, Karki, Sher, Leung, Irene W L, Sproule, Thomas J, Lazar, Greg A, Roopenian, Derry C, Desjarlais, John R

Volltext

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma von Diab, Adi, Tykodi, Scott S, Daniels, Gregory A, Maio, Michele, Curti, Brendan D, Lewis, Karl D, Jang, Sekwon, Kalinka, Ewa, Puzanov, Igor, Spira, Alexander I, Cho, Daniel C, Guan, Shanhong, Puente, Erika, Nguyen, Tuan, Hoch, Ute, Currie, Sue L, Lin, Wei, Tagliaferri, Mary A, Zalevsky, Jonathan, Sznol, Mario, Hurwitz, Michael E

Volltext

The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled ph... von Silverberg, Jonathan I., Rosmarin, David, Chovatiya, Raj, Bieber, Thomas, Schleicher, Stephen, Beck, Lisa, Gooderham, Melinda, Chaudhry, Sohail, Fanton, Christie, Yu, Danni, Levy, Joshua, Liu, Yi, Miyazaki, Takahiro, Tagliaferri, Mary, Schmitz, Carsten, Nirula, Ajay, Kotzin, Brian, Zalevsky, Jonathan

Volltext

Recent patents in allergy and immunology: The interleukin‐2 receptor pathway agonist rezpegaldesleukin (REZPEG) for the rescue of regulatory T cells in chronic inflammatory and aut... von Fanton, Christie, Zalevsky, Jonathan

Volltext

Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in Rodents von Kopruszinski, Caroline M., Swiokla, Juliana, Lee, Yeon Sun, Navratilova, Edita, VanderVeen, Laurie, Yang, Miao, Liu, Yi, Miyazaki, Takahiro, Schmidt, William K., Zalevsky, Jonathan, Porreca, Frank

Volltext

NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy von Miyazaki, Takahiro, Maiti, Mekhala, Hennessy, Marlene, Chang, Thomas, Kuo, Peiwen, Addepalli, Murali, Obalapur, Palakshi, Sheibani, Sara, Wilczek, Joanna, Pena, Rhoneil, Quach, Phi, Cetz, Janet, Moffett, Andrew, Tang, Yinyan, Kirk, Peter, Huang, Jicai, Sheng, Dawei, Zhang, Ping, Rubas, Werner, Madakamutil, Loui, Kivimäe, Saul, Zalevsky, Jonathan

Volltext

Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus von Fanton, Christie, Furie, Richard, Chindalore, Vishala, Levin, Robert, Diab, Isam, Dixit, Neha, Haglund, Cat, Gibbons, Jacqueline, Hanan, Nathan, Dickerson, Daniel, Zalevsky, Jonathan, Kotzin, Brian L.

Volltext

NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory... von Dixit, Neha, Fanton, Christie, Langowski, John L., Kirksey, Yolanda, Kirk, Peter, Chang, Thomas, Cetz, Janet, Dixit, Vidula, Kim, Grace, Kuo, Peiwen, Maiti, Mekhala, Tang, Yinyan, VanderVeen, Laurie A., Zhang, Ping, Lee, Myong, Ritz, Jerome, Kamihara, Yusuke, Ji, Chunmei, Rubas, Werner, Sweeney, Theresa D., Doberstein, Stephen K., Zalevsky, Jonathan

Volltext

Soluble TNF mediates the transition from pulmonary inflammation to fibrosis von Oikonomou, Nikos, Harokopos, Vaggelis, Zalevsky, Jonathan, Valavanis, Christos, Kotanidou, Anastasia, Szymkowski, David E, Kollias, George, Aidinis, Vassilis

Volltext

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study von Tannir, Nizar M, Cho, Daniel C, Diab, Adi, Sznol, Mario, Bilen, Mehmet A, Balar, Arjun V, Grignani, Giovanni, Puente, Erika, Tang, Lily, Chien, David, Hoch, Ute, Choudhury, Arkopal, Yu, Danni, Currie, Sue L, Tagliaferri, Mary A, Zalevsky, Jonathan, Siefker-Radtke, Arlene O, Hurwitz, Michael E

Volltext

Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection von Zalevsky, Jonathan, Secher, Thomas, Ezhevsky, Sergei A, Janot, Laure, Steed, Paul M, O'Brien, Christopher, Eivazi, Araz, Kung, James, Nguyen, Duc-Hanh T, Doberstein, Stephen K, Erard, Francois, Ryffel, Bernhard, Szymkowski, David E

Volltext

Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab von Veatch, Joshua R, Singhi, Naina, Jesernig, Brenda, Paulson, Kelly G, Zalevsky, Jonathan, Iacucci, Ernesto, Tykodi, Scott S, Riddell, Stanley R

Volltext

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion von D'Alise, Anna Morena, Leoni, Guido, De Lucia, Maria, Langone, Francesca, Nocchi, Linda, Tucci, Fabio Giovanni, Micarelli, Elisa, Cotugno, Gabriella, Troise, Fulvia, Garzia, Irene, Vitale, Rosa, Bignone, Veronica, Di Matteo, Elena, Bartolomeo, Rosa, Charych, Deborah H, Lahm, Armin, Zalevsky, Jonathan, Nicosia, Alfredo, Scarselli, Elisa

Volltext

In vivo and in vitro Characterization of a Partial Mu Opioid Receptor Agonist, NKTR-181, Supports Future Therapeutic Development von Lee, Alex S, Tiwari, Suchi, Bishop, Isabel, Matossian, Vartan, Romaneschi, Nicole, Miyazaki, Takahiro, VanderVeen, Laurie, Zalevsky, Jonathan, DeFea, Kathryn, Cahill, Catherine M, Walwyn, Wendy M

Volltext

Engineering IL-2 to Give New Life to T Cell Immunotherapy von Overwijk, Willem W, Tagliaferri, Mary A, Zalevsky, Jonathan

Volltext

368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for tre... von Diab, Adi, Curti, Brendan, Bilen, Mehmet, Brohl, Andrew, Domingo-Musibay, Evidio, Borazanci, Erkut, Fanton, Christie, Haglund, Cat, Vimal, Mona, Muhsin, Mann, Marcondes, Mario, Nguyen, Anh, Tagliaferri, Mary, Lin, Wei, Zalevsky, Jonathan, D’Angelo, Sandra

Volltext

420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study... von Diab, Adi, Tykodi, Scott, Daniels, Gregory, Maio, Michele, Curti, Brendan, Lewis, Karl, Jang, Sekwon, Kalinka, Ewa, Puzanov, Igor, Spira, Alexander, Cho, Daniel, Guan, Shanhong, Puente, Erika, Hoch, Ute, Currie, Sue, Nguyen, Tuan, Lin, Wei, Tagliaferri, Mary, Zalevsky, Jonathan, Sznol, Mario, Hurwitz, Michael

Volltext